[go: up one dir, main page]

TR200200515T2 - Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması. - Google Patents

Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması.

Info

Publication number
TR200200515T2
TR200200515T2 TR2002/00515T TR200200515T TR200200515T2 TR 200200515 T2 TR200200515 T2 TR 200200515T2 TR 2002/00515 T TR2002/00515 T TR 2002/00515T TR 200200515 T TR200200515 T TR 200200515T TR 200200515 T2 TR200200515 T2 TR 200200515T2
Authority
TR
Turkey
Prior art keywords
renin
angiotensin system
prevention
inhibitor
pharmaceutically acceptable
Prior art date
Application number
TR2002/00515T
Other languages
English (en)
Inventor
Schoelkens Bernward
Bender Norbert
Rangoonwala Badrudin
Yusuf Sal�M
Gerstein Hertzel
Daganais Gilles
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22538761&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200200515(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of TR200200515T2 publication Critical patent/TR200200515T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)

Abstract

Mevcut bulus, renin-anjiyotensin sisteminin bir önleyicisinin veya bunun farmasötik açidan kabul edilebilir bir tuzunun, istege bagli olarak bir baska anti hipertansiyon maddesi, kolesterol düsürme maddesi diüretik veya aspirinle birlikte, kardiyovasküler vakalarin engellenmesi amaçli bir ilacin üretiminde kullanilmasi; bu tür engellemeye ihtiyaç duyan bir hastaya, renin anjiyotensin sisteminin önleyicisi veya bunun farmasötik açidan kabul edilebilir tuzundan etkili bir miktarin, istege bagli olarak bir baska anti hipertansiyon maddesi, kolesterol düsürme maddesi, diüretik veya aspirinle birlikte verilmesinden olusan, kardiyovasküler vakalarin engellenmesi yöntemi; veya renin-anjiyotensin sisteminin bir önleyicisini veya bunun farmasötik açidan kabul edilebilir bir tuzunu ve bir kolesterol düsürme maddesini içeren bir kombinasyon ürünüyle ilgilidir.
TR2002/00515T 1999-08-30 2000-08-30 Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması. TR200200515T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15143699P 1999-08-30 1999-08-30

Publications (1)

Publication Number Publication Date
TR200200515T2 true TR200200515T2 (tr) 2002-11-21

Family

ID=22538761

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00515T TR200200515T2 (tr) 1999-08-30 2000-08-30 Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması.

Country Status (31)

Country Link
US (4) US20040087645A1 (tr)
EP (1) EP1216038B1 (tr)
JP (1) JP4870888B2 (tr)
KR (2) KR20120055730A (tr)
CN (1) CN1268331C (tr)
AT (1) ATE303800T1 (tr)
AU (3) AU7649100A (tr)
BG (2) BG110003A (tr)
BR (1) BR0013704A (tr)
CA (1) CA2382549C (tr)
CZ (1) CZ300687B6 (tr)
DE (1) DE60022525T2 (tr)
DK (1) DK1216038T3 (tr)
EE (1) EE05670B1 (tr)
ES (1) ES2246894T3 (tr)
HK (1) HK1048267B (tr)
HR (1) HRP20020170A2 (tr)
HU (1) HUP0203326A3 (tr)
IL (2) IL148127A0 (tr)
ME (1) ME00429B (tr)
MX (1) MXPA02001694A (tr)
NO (1) NO331616B1 (tr)
NZ (2) NZ517468A (tr)
PL (1) PL353199A1 (tr)
RS (1) RS50377B (tr)
RU (2) RU2276997C2 (tr)
SK (1) SK2692002A3 (tr)
TR (1) TR200200515T2 (tr)
UA (2) UA77151C2 (tr)
WO (1) WO2001015674A2 (tr)
ZA (1) ZA200201470B (tr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL193215B1 (pl) * 1997-10-17 2007-01-31 Eurogene Ltd Zastosowanie lipofilnych inhibitorów układu renina-angiotensyna
CN101011390A (zh) * 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
MXPA02001694A (es) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
MXPA03001509A (es) * 2000-08-22 2003-06-09 Boehringer Ingelheim Pharma Combinacion farmaceutica de antagonistas de la angiotensina ii e inhibidores de la enzima de conversion de la angiotensina i.
US20060089389A1 (en) * 2000-08-22 2006-04-27 Malcolm Allison Combination
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
GB0119460D0 (en) * 2001-08-09 2001-10-03 Ark Therapeutics Ltd The use of inhibitors of the renin-angiotensin system
US6576256B2 (en) 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
WO2003032963A2 (en) * 2001-10-17 2003-04-24 Aventis Pharma Deutschland Gmbh Method of reducing type 2 diabetes in high risk patients
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia
DE10229180A1 (de) * 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
EP1553941A1 (en) * 2002-10-16 2005-07-20 Recordati Ireland Limited Lisinopril/lercanidipine combination therapy
SI1587584T1 (sl) * 2003-01-16 2007-10-31 Boehringer Ingelheim Int Farmacevtska kombinacija za profilakso ali terapijo kardiovaskularnih, kardiopulmonalnih, pulmonalnih ali renalnih bolezni
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
WO2004067003A1 (ja) * 2003-01-31 2004-08-12 Sankyo Company, Limited 動脈硬化及び高血圧症の予防及び治療のための医薬
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US7169805B2 (en) * 2003-05-28 2007-01-30 Nicox S.A. Captopril derivatives
JP2009513543A (ja) * 2003-07-16 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング クロルタリドンの組み合わせ
CN1822820A (zh) * 2003-07-28 2006-08-23 雷迪实验室有限公司 心血管疾病的治疗和预防
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
US20080161321A1 (en) * 2004-03-17 2008-07-03 David Louis Feldman Use of Renin Inhibitors in Therapy
CN1972679B (zh) * 2004-06-23 2010-07-28 索尔瓦药物有限公司 包括nep-抑制剂、内源性内皮缩血管肽产生系统抑制剂和at1受体拮抗剂的药物组合物
JP4675586B2 (ja) * 2004-06-23 2011-04-27 壽製薬株式会社 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
AU2005301989A1 (en) * 2004-11-05 2006-05-11 King Pharmaceuticals Research & Development, Inc. Stabilized individually coated ramipril particles, compositions and methods
ATE518526T1 (de) * 2005-01-26 2011-08-15 Lek Pharmaceuticals Neue pharmazeutische zusammensetzung mit candesartan-cilexetil als lipophile kristalline substanz
TWI405580B (zh) * 2005-06-27 2013-08-21 Sankyo Co 含有血管收縮素ｉｉ接受器拮抗劑及鈣通道阻斷劑之醫藥調配物
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
WO2007053406A1 (en) * 2005-10-28 2007-05-10 Novartis Ag Combinations of antihypertensive and cholesterol lowering agents
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
CN101573110A (zh) * 2006-08-28 2009-11-04 塞诺菲-安万特德国有限公司 降低葡萄糖水平的方法
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
US8394845B2 (en) 2006-10-30 2013-03-12 Hanall Biopharma Co., Ltd. Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor
CN102973942B (zh) * 2006-10-30 2015-08-12 韩诺生物制约株式会社 包含血管紧张素II受体阻断剂和HMG-CoA还原酶抑制剂的控释复合组合物
US20100143470A1 (en) * 2006-10-30 2010-06-10 Hanall Pharmaceutical Company, Ltd Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
RU2400223C1 (ru) * 2009-03-30 2010-09-27 Илья Николаевич Медведев Способ нормализации функциональной реактивности сердечно-сосудистой системы при сочетании артериальной гипертонии со стенокардией i-ii функциональных классов
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
WO2011063339A1 (en) * 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
WO2011071947A2 (en) * 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
CN102753520B (zh) * 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
MA34130B1 (fr) 2010-02-24 2013-04-03 Sanofi Aventis Deutschland Formulations pharmaceutiques solides de ramipril et de bésylate d'amlodipine et leur préparation
WO2012087090A1 (es) * 2010-12-21 2012-06-28 Laboratorios Silanes S.A. De C.V. Composición estable de agentes reductores de colesterol, antihipertensivos y antiagregantes plaquetarios
BR102012020648A2 (pt) * 2012-08-17 2014-12-09 Hypermarcas S A Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido
KR101579656B1 (ko) * 2013-12-12 2015-12-22 가천대학교 산학협력단 프라바스타틴과 발사르탄을 포함하는 약학 조성물
CN110833620A (zh) * 2018-08-15 2020-02-25 王镕 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5612114B2 (tr) * 1974-06-07 1981-03-18
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) * 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
ZA817261B (en) * 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
DE3226768A1 (de) * 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
US4448784A (en) * 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
US4722810A (en) * 1984-08-16 1988-02-02 E. R. Squibb & Sons, Inc. Enkephalinase inhibitors
DE3413710A1 (de) * 1984-04-12 1985-10-24 Hoechst Ag, 6230 Frankfurt Verfahren zur behandlung der herzinsuffizienz
US5684016A (en) * 1984-04-12 1997-11-04 Hoechst Aktiengesellschaft Method of treating cardiac insufficiency
CH672792A5 (tr) 1985-02-19 1989-12-29 Sandoz Ag
US5231080A (en) * 1985-10-15 1993-07-27 Hoechst Aktiengesellschaft Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease
EP0241201A3 (en) 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
DE3633496A1 (de) * 1986-10-02 1988-04-14 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
DE3704661A1 (de) * 1987-02-14 1988-08-25 Hoechst Ag Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
JPH0657707B2 (ja) 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
DE3739690A1 (de) 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
EP0331014A3 (de) * 1988-03-02 1991-10-23 THERA - Patent Verwaltungs-GmbH Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe
US5217958A (en) * 1988-03-03 1993-06-08 E. R. Squibb & Sons, Inc. 1,2-hydroxy phosphonates and derivatives thereof
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
DE3818245A1 (de) * 1988-05-28 1989-12-07 Hoechst Ag Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln
MY105067A (en) 1988-10-13 1994-07-30 Novartis Ag Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof.
EP0444156A4 (en) * 1988-11-21 1992-12-09 Abbott Laboratories Method for treating vascular diseases
CA2016467A1 (en) * 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
DE3926606A1 (de) * 1989-08-11 1991-02-14 Hoechst Ag Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie
US5061694A (en) * 1989-10-23 1991-10-29 E. R. Squibb & Sons, Inc. Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor
US5212165A (en) * 1989-10-23 1993-05-18 E. R. Squibb & Sons, Inc. Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor
CA2026686A1 (en) 1989-10-30 1991-05-01 Werner Tschollar Method for preventing onset of type ii diabetes employing an ace inhibitor
US5223516A (en) * 1990-03-22 1993-06-29 E. R. Squibb & Sons, Inc. 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
CA2040865C (en) 1990-05-15 2002-07-23 James L. Bergey Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
US5140012A (en) 1990-05-31 1992-08-18 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing pravastatin
US5166143A (en) * 1990-05-31 1992-11-24 E. R. Squibb & Sons, Inc. Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
CA2042526A1 (en) 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
CA2048699A1 (en) 1990-09-04 1992-03-05 Abraham Sudilovsky Method for preventing or treating cerebro-vascular disease employing ceronapril
US5470975A (en) * 1990-10-16 1995-11-28 E.R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
CA2053340C (en) 1990-10-18 2002-04-02 Timothy P. Burkholder Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5430145A (en) * 1990-10-18 1995-07-04 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
CA2052014A1 (en) 1990-10-19 1992-04-20 Henry Y. Pan Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
GB9027199D0 (en) 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
US5157025A (en) 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5506361A (en) * 1991-05-08 1996-04-09 Theupjohn Company Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
JPH05112533A (ja) 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤
GB9110635D0 (en) * 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
US5225401A (en) * 1991-08-12 1993-07-06 E. R. Squibb & Sons, Inc. Treatment of congestive heart failure
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ZA927211B (en) 1991-09-27 1993-03-24 Merrell Dow Pharma Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE.
JPH06107661A (ja) 1991-10-24 1994-04-19 Upjohn Co:The イミダゾール誘導体およびこれを有効成分とする医薬組成物
US5350752A (en) 1991-12-16 1994-09-27 E. R. Squibb & Sons, Inc. Dihydropyrimidine derivatives
DK9200258U4 (da) 1992-03-11 1993-07-23 Merck & Co Inc Farmaceutisk præparat indeholdende enalapril til brug mod hypertension
US5219856A (en) * 1992-04-06 1993-06-15 E. I. Du Pont De Nemours And Company Angiotensin-II receptor blocking, heterocycle substituted imidazoles
US5972990A (en) 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5977160A (en) * 1992-04-10 1999-11-02 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
HU223663B1 (hu) * 1992-05-15 2004-11-29 Merrel Dow Pharmaceuticals Inc. Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
JPH07509464A (ja) * 1992-07-17 1995-10-19 メルク　エンド　カンパニー　インコーポレーテッド 置換ビフェニルメチルイミダゾピリジン
US5266583A (en) * 1992-09-01 1993-11-30 Merck & Co., Inc. Angitotensin II antagonist
AU5096893A (en) 1992-10-06 1994-04-26 Upjohn Company, The Use of 4-hydrazono-1,4-dihydro-pyridine and/or 4-hydrazino-pyridine derivatives for treatment of hypertension and congestive heart failure
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
GB9223860D0 (en) * 1992-11-13 1993-01-06 Glaxo Group Ltd Chemical compounds
DE4308504A1 (de) 1993-03-18 1994-09-22 Knoll Ag Neue Verwendung einer Kombination aus Verapamil und Trandolapril
DE4309553A1 (de) * 1993-03-24 1994-09-29 Bayer Ag Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat
CA2140553A1 (en) * 1993-06-11 1994-12-22 Hitoshi Oinuma Amino acid derivative
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
US5362772A (en) * 1993-07-09 1994-11-08 E. I. Du Pont De Nemours And Company Crosslinked microgel for cathodic electrocoating compositions
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
AU1095695A (en) 1993-11-09 1995-05-29 Brigham And Women's Hospital Hmg-coa reductase inhibitors in the normalization of vascular endothelial dysfunction
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
US6369103B1 (en) 1994-01-18 2002-04-09 Bristol-Myers Squibb Company Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
ES2079315B1 (es) * 1994-02-24 1996-10-16 Uriach & Cia Sa J Nuevas imidazopiridinas.
IL112639A0 (en) 1994-03-11 1995-05-26 Bristol Myers Squibb Co A pharmaceutical composition containing pravastin
AU696868B2 (en) 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
ES2105939B1 (es) * 1994-08-02 1998-07-01 Uriach & Cia Sa J Nuevos pirazoles con actividad antagonista de la angiotensina ii.
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
TW483763B (en) 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
JPH11507012A (ja) 1995-02-10 1999-06-22 ジー．ディー．サール アンド カンパニー 心臓血管系病気の処置におけるアンギオテンシン変換酵素阻害薬と副作用軽減量のアルドステロン拮抗薬との組合わせ治療
EP0738510A3 (fr) 1995-04-20 2005-12-21 L'oreal Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes
US5656603A (en) * 1995-05-31 1997-08-12 Loyola University Of Chicago Aminopeptidase P inhibitors and uses thereof
TW442301B (en) 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
DE69620756T2 (de) 1995-06-07 2002-11-14 G.D. Searle & Co., Chicago Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist
GB2308064A (en) 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
AU2252297A (en) 1996-01-31 1997-08-22 Technology Licensing Co., L.L.C. Method of diagnosis and treatment and related compositions and apparatus
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
EP0910375B1 (en) 1996-06-24 2002-05-02 Merck & Co., Inc. A composition of enalapril and losartan
JPH1081633A (ja) * 1996-07-16 1998-03-31 Sankyo Co Ltd 医薬組成物
ES2200310T3 (es) 1997-01-10 2004-03-01 MERCK & CO., INC. Uso de antagonistas de la angiotensina ii losartan y exp-3174 en el tratamiento de la insuficiencia cardiaca sintomatica.
US6180660B1 (en) * 1997-08-26 2001-01-30 Merck & Co., Inc. Cholesterol-lowering therapy
EP1007019A2 (en) 1997-08-26 2000-06-14 Merck & Co., Inc. Cholesterol-lowering therapy
GT199800126A (es) 1997-08-29 2000-01-29 Terapia de combinacion.
PL193215B1 (pl) * 1997-10-17 2007-01-31 Eurogene Ltd Zastosowanie lipofilnych inhibitorów układu renina-angiotensyna
KR20010086245A (ko) 1998-03-04 2001-09-10 다케다 야쿠힌 고교 가부시키가이샤 Ａⅱ 길항제용 서방성 제제, 그것의 제조 및 용도
SK285863B6 (sk) 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
BR9914098A (pt) 1998-09-30 2001-07-31 Warner Lambert Co Método para impedir ou retardar revascularização à base de cateter
US6403856B1 (en) * 1998-10-19 2002-06-11 Uop Llc Process for separating alkylaromatic hydrocarbons
DE19913528A1 (de) 1998-12-21 2000-06-29 Sanol Arznei Schwarz Gmbh Neue Verwendung von Moexipril
GB0001662D0 (en) 1999-02-06 2000-03-15 Zeneca Ltd Pharmaceutical compositions
WO2000067737A2 (en) 1999-05-07 2000-11-16 The Brigham And Women's Hospital, Inc. USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION
AU5016200A (en) 1999-05-21 2000-12-12 Myriad Genetics, Inc. Diabetes gene
EP1076091A1 (en) 1999-08-09 2001-02-14 Universite Catholique De Louvain Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
MXPA02001694A (es) * 1999-08-30 2002-08-06 Aventis Pharma Gmbh Uso de inhibidores del sistema renina-angiotensina en la prevencion de eventos cardiovasculares.
AU782386C (en) 1999-08-31 2006-08-10 Brigham And Women's Hospital Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
EP1272220B2 (en) 2000-04-10 2016-07-27 Nicholas John Wald Formulation for the prevention of cardiovascular disease
SK14642002A3 (sk) 2000-04-12 2003-05-02 Novartis Ag Kombinované farmaceutické prostriedky obsahujúce antagonistu AT1-receptora a/alebo inhibítor HMG-CoA reduktázy a/alebo ACE inhibítor
AU2001256278A1 (en) 2000-04-18 2001-10-30 Bayer Aktiengesellschaft Use of cse inhibitors for treating heart failure
GB0020691D0 (en) * 2000-08-22 2000-10-11 Boehringer Ingelheim Pharma Pharmaceutical combination
US20030158090A1 (en) * 2001-07-23 2003-08-21 Ulrik Pedersen-Bjergaard Renin-angiotensin system in diabetes mellitus
US20050065203A1 (en) * 2001-10-17 2005-03-24 Salim Yusuf Method of reducing type 2 diabetes in high risk patients
BR0214383A (pt) * 2001-11-23 2004-11-03 Solvay Pharm Gmbh Tratamento de hipertonia durante a fase aguda do ataque de apoplexia

Also Published As

Publication number Publication date
US20040087645A1 (en) 2004-05-06
PL353199A1 (en) 2003-11-03
EE200200086A (et) 2003-04-15
CN1268331C (zh) 2006-08-09
KR20020040795A (ko) 2002-05-30
IL148127A0 (en) 2002-09-12
AU2009200746B2 (en) 2011-07-28
WO2001015674A3 (en) 2002-03-28
HUP0203326A3 (en) 2003-04-28
UA88265C2 (ru) 2009-10-12
CN1368881A (zh) 2002-09-11
KR20120055730A (ko) 2012-05-31
AU2009200746B8 (en) 2011-08-18
CZ2002770A3 (cs) 2002-06-12
HRP20020170A2 (en) 2005-10-31
RU2005141759A (ru) 2007-07-10
NO20020978D0 (no) 2002-02-27
NZ517468A (en) 2004-02-27
HUP0203326A2 (hu) 2003-02-28
ZA200201470B (en) 2003-09-23
US20080287403A1 (en) 2008-11-20
US7368469B2 (en) 2008-05-06
CA2382549A1 (en) 2001-03-08
ATE303800T1 (de) 2005-09-15
EP1216038B1 (en) 2005-09-07
AU2005209687A1 (en) 2005-10-06
DE60022525T2 (de) 2006-06-14
BG65474B1 (bg) 2008-09-30
MXPA02001694A (es) 2002-08-06
BR0013704A (pt) 2002-05-07
EE05670B1 (et) 2013-08-15
CA2382549C (en) 2005-03-15
JP4870888B2 (ja) 2012-02-08
DK1216038T3 (da) 2005-12-27
JP2003527325A (ja) 2003-09-16
NO331616B1 (no) 2012-02-06
AU2009200746A1 (en) 2009-03-19
RS50377B (sr) 2009-11-10
HK1048267A1 (en) 2003-03-28
US20050101658A1 (en) 2005-05-12
NO20020978L (no) 2002-04-18
AU7649100A (en) 2001-03-26
DE60022525D1 (de) 2005-10-13
EP1216038A2 (en) 2002-06-26
RU2276997C2 (ru) 2006-05-27
ME00429B (me) 2011-10-10
ES2246894T3 (es) 2006-03-01
WO2001015674A2 (en) 2001-03-08
IL148127A (en) 2015-07-30
SK2692002A3 (en) 2002-07-02
HK1048267B (zh) 2006-12-08
UA77151C2 (en) 2006-11-15
CZ300687B6 (cs) 2009-07-15
US20070021491A1 (en) 2007-01-25
YU8502A (sh) 2004-12-31
BG106360A (en) 2002-10-31
NZ530702A (en) 2005-07-29
BG110003A (bg) 2008-06-30

Similar Documents

Publication Publication Date Title
TR200200515T2 (tr) Renin-anjiyotensin sistem önleyicilerinin kardiyovasküler vakaların engellenmesinde kullanılması.
WO2005011586A3 (en) Treatment and preventi0n of cardiovascular events
IL163380A (en) Treating benign prostate hyperplasia with sarms
WO2003088958A3 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
BG104779A (en) Inhibitors of phospholipase enzymes
WO2001076574A3 (en) Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
EP1776954A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of stroke
PL322576A1 (en) Transdermally administered therapeutic agent containing inhibitors of angiotensin convertase
IL131348A0 (en) Treatment and prevention of adhesions
MY124648A (en) Inhibitor of factor xa alone or in combination with an anti-platelet aggregation agent, for combating arterial thrombosis.
TR199801705T2 (tr) Serin proteaz inhibitörleri.
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2001056555A3 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2003101380A3 (en) Amyotrophic lateral sclerosis treatment with cyclooxygenase-2 inhibitors
DE60108495D1 (en) Thrombin inhibitoren
EP1611886A3 (en) Inhibitors of the renin-angiotensin system for the prevention of cardiovascular disorders
WO2002096516A8 (en) Use of compositions comprising cyclooxygenase-2 selective inhibitors in combination with radiation for inhibition or prevention of cardiovascular disease
WO2001000189A3 (de) Kombination von mtp-inhibitoren und stoffwechselbeeinflussenden wirkstoffen und ihre verwendung in arzneimitteln
SG148838A1 (en) Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
WO2005039638A3 (en) Therapeutic agent for heart failure comprising an angiotensin ii receptor antagonist and a matrix metalloproteinase inhibitor